Buy Stocks Easy | About Us
September 24, 2020
Buy Stocks Easy | Online Stocks

ANAB


Buy AnaptysBio, Inc. Stock (symbol: ANAB) Easy Online

Company Name: AnaptysBio, Inc.

Symbol: ANAB

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2017

ANAB Current Share Price

Today's ANAB ( AnaptysBio, Inc. ) opening price: $16.5200

Yesterday's ANAB ( AnaptysBio, Inc. ) closing price: $16.4100

AnaptysBio, Inc. Stock ( symbol: ANAB ) Price Chart since IPO (2017):

12 Months AnaptysBio, Inc. Stock ( symbol: ANAB ) Price Chart

Popular Questions about AnaptysBio, Inc. Public Stock ( ANAB )

A: AnaptysBio, Inc. stock symbol (also called stock or share ticker) is ANAB

A: AnaptysBio, Inc. IPO (Initial Public Offering) took place on 2017

A: AnaptysBio, Inc.'s stock (ANAB symbol) price at ther IPO (initial Public Offering) was $16.5200

Q: Is ANAB stock worth buying at the moment?

A: The ANAB stock performance since 2019 are rather disappointing. If you had bought 1 share of AnaptysBio, Inc. stock (symbol: ANAB) at the beginning of 2019, at the opening share price of $66.3200, you would be left with exactly $16.5200 - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy AnaptysBio, Inc. Stock Easy Online

AnaptysBio, Inc. Stock Ticker Price Chart since IPO:





AnaptysBio, Inc. Stock Price Yesterday



 


AnaptysBio, Inc. Stock Price – Last Week




 


AnaptysBio, Inc. Stock Price – Last Month




 


AnaptysBio, Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.gurufocus.com/news/990785/analysts-see-these-2-falling-knives-rebounding-within-a-year-
                            

                                
Analysts See These 2 Falling Knives Rebounding Within a Year

                                
                                
Falling knives are companies whose share prices have declined more ...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4305655-anaptysbio-due-bounce-trades-significantly-net-cash-per-share
                            

                                
AnaptysBio Is Due For A Bounce As It Trades Significantly Below Its Net Cash Per Share

                                
                                
AnaptysBio Is Due For A Bounce As It Trades Significantly Below Its...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/614143/anaptysbio-enters-oversold-territory
                            

                                
AnaptysBio Enters Oversold Territory

                                
                                
AnaptysBio has been on a bit of a cold streak lately, but there mig...


                            

                        
                    

                


                            

                    


                        
                            https://www.benzinga.com/general/biotech/19/11/14768723/anaptysbio-shares-crater-on-failed-eczema-study
                            

                                
AnaptysBio Shares Crater On Failed Eczema Study

                                
                                
AnaptysBio Inc (NASDAQ: ANAB) shares were taking a huge hit after t...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/610157/anaptysbio-inc-anab-reports-q3-loss-lags-revenue-estimates
                            

                                
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Lags Revenue Estimates

                                
                                
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/08/1944020/0/en/AnaptysBio-Reports-Etokimab-ATLAS-Phase-2b-Clinical-Trial-in-Moderate-to-Severe-Atopic-Dermatitis-Fails-to-Meet-Primary-Endpoint.html
                            

                                
AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint

                                
                                
SAN DIEGO, Nov.  08, 2019  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Na...


                            

                        
                    

                


                            

                    


                        
                            http://www.gurufocus.com/news/990785/analysts-see-these-2-falling-knives-rebounding-within-a-year-
                            

                                
Analysts See These 2 Falling Knives Rebounding Within a Year

                                
                                
Falling knives are companies whose share prices have declined more ...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4305655-anaptysbio-due-bounce-trades-significantly-net-cash-per-share
                            

                                
AnaptysBio Is Due For A Bounce As It Trades Significantly Below Its Net Cash Per Share

                                
                                
AnaptysBio Is Due For A Bounce As It Trades Significantly Below Its...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/614143/anaptysbio-enters-oversold-territory
                            

                                
AnaptysBio Enters Oversold Territory

                                
                                
AnaptysBio has been on a bit of a cold streak lately, but there mig...


                            

                        
                    

                


                            

                    


                        
                            https://www.benzinga.com/general/biotech/19/11/14768723/anaptysbio-shares-crater-on-failed-eczema-study
                            

                                
AnaptysBio Shares Crater On Failed Eczema Study

                                
                                
AnaptysBio Inc (NASDAQ: ANAB) shares were taking a huge hit after t...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/610157/anaptysbio-inc-anab-reports-q3-loss-lags-revenue-estimates
                            

                                
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Lags Revenue Estimates

                                
                                
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/08/1944020/0/en/AnaptysBio-Reports-Etokimab-ATLAS-Phase-2b-Clinical-Trial-in-Moderate-to-Severe-Atopic-Dermatitis-Fails-to-Meet-Primary-Endpoint.html
                            

                                
AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint

                                
                                
SAN DIEGO, Nov.  08, 2019  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Na...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.